Last reviewed · How we verify
Standard 2016-2017 Flu vaccine
The 2016-2017 flu vaccine works by stimulating the body's immune system to produce antibodies against the flu virus.
The 2016-2017 flu vaccine works by stimulating the body's immune system to produce antibodies against the flu virus. Used for Influenza prevention.
At a glance
| Generic name | Standard 2016-2017 Flu vaccine |
|---|---|
| Sponsor | University Health Network, Toronto |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This is achieved through the introduction of inactivated flu virus particles, which trigger an immune response without causing the disease. The immune system then produces antibodies that can recognize and neutralize the flu virus, providing protection against future infections.
Approved indications
- Influenza prevention
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
- Open-Label Influenza Vaccine Evaluation (NA)
- High Dose vs. Standard Influenza Vaccine in Adult SOT (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard 2016-2017 Flu vaccine CI brief — competitive landscape report
- Standard 2016-2017 Flu vaccine updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI